These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 29683766

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
    Zhang T, Liu H, Chen X, Wang Z, Wang S, Qu C, Zhang J, Xu X.
    Vaccine; 2016 Nov 04; 34(46):5531-5539. PubMed ID: 27729176
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice.
    Motavalli Khiavi F, Arashkia A, Golkar M, Nasimi M, Roohvand F, Azadmanesh K.
    J Immunol Res; 2018 Nov 04; 2018():9464186. PubMed ID: 29854852
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Development of an HPV vaccine for a broad spectrum of high-risk types.
    Kanda T, Kondo K.
    Hum Vaccin; 2009 Nov 04; 5(1):43-5. PubMed ID: 18690012
    [Abstract] [Full Text] [Related]

  • 30. Induction of cross-neutralizing antibodies by sequential immunization with heterologous papillomavirus L1VLPs and its implications for HPV prophylactic vaccines.
    Zhang T, Chen X, Liao G, Hu M, Xu J, Xu X.
    J Med Virol; 2020 Dec 04; 92(12):3750-3758. PubMed ID: 31994744
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® Vaccine.
    Godi A, Bissett SL, Miller E, Beddows S.
    PLoS One; 2015 Dec 04; 10(10):e0140926. PubMed ID: 26495976
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.
    Jagu S, Kwak K, Garcea RL, Roden RB.
    Vaccine; 2010 Jun 17; 28(28):4478-86. PubMed ID: 20434552
    [Abstract] [Full Text] [Related]

  • 36. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
    Seitz H, Ribeiro-Müller L, Canali E, Bolchi A, Tommasino M, Ottonello S, Müller M.
    Cancer Prev Res (Phila); 2015 Oct 17; 8(10):932-41. PubMed ID: 26170394
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC, Zarnitsyn V, Johnson TR, Pang YY, Corbett KS, Nicewonger JD, Gangopadhyay A, Chen M, Liu J, Prausnitz MR, Schiller JT, Graham BS.
    PLoS One; 2015 Oct 17; 10(3):e0120797. PubMed ID: 25785935
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.